About
Elevating human life through scientific innovation.
Science
Developing gene therapies to reduce patient suffering.
| Indication | Developmental stage | Transgene | Injection route | Serotype |
|---|---|---|---|---|
| Chronic Neuropathic Pain | Preclinical | Anti-Fam19a5 scFv | Intrathecal Injection | TBD |
Neuropathic pain is a difficult-to-manage chronic condition arising from somatosensory nervous system lesions, leading to persistent hypersensitivity and decreased quality of life.
The DRG is a key structure where neuron-glia bidirectional signaling occurs; its dysregulation is heavily linked to persistent sensitization in chronic pain.
Standard treatments (e.g., gabapentinoids, SNRIs) require complex, long-term daily regimens. Real-world outcomes are limited by incomplete relief and tolerability issues, driving cumulative burden and poor adherence.
This highlights the need for therapies targeting.
EG201 is an investigational AAV gene therapy designed to establish a mechanism-driven paradigm for chronic pain through single-dose delivery of an anti-FAM19A5 scFv. The therapy targets FAM19A5, a secreted factor implicated in the persistence of pain. FAM19A5 is proposed to regulate the association between dorsal root ganglion (DRG) neurons and satellite glial cells, and by precisely modulating this mechanism, EG201 offers a therapeutic approach distinct from conventional analgesic targets.
In preclinical rodent studies, EG201 suppressed pain-related behaviors and restored disrupted neuron–glia association in the DRG. Treated naïve animals showed no hyposensitivity, supporting a selective and safe therapeutic profile. The secreted domain of FAM19A5 and the neuron–glia architecture of the mammalian DRG are highly conserved across species, suggesting that efficacy observed in rodents is likely to translate to humans — positioning EG201 to deliver durable, mechanism-driven pain control from a single treatment.
